|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:ATCCode
|
gptkb:N04BD02
|
|
gptkbp:brand
|
gptkb:Eldepryl
gptkb:Emsam
gptkb:Zelapar
|
|
gptkbp:CASNumber
|
gptkb:14611-51-9
|
|
gptkbp:category
|
amphetamine
stimulant
antiparkinsonian agent
antidepressant
monoamine oxidase inhibitor
propargylamine
|
|
gptkbp:chirality
|
R-enantiomer is active
|
|
gptkbp:contraindication
|
concomitant use with SSRIs
concomitant use with meperidine
|
|
gptkbp:discoveredBy
|
Joseph Knoll
|
|
gptkbp:discoveredIn
|
1964
|
|
gptkbp:hasMolecularFormula
|
C13H17N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
deprenyl
|
|
gptkbp:IUPACName
|
(R)-N,α-dimethyl-N-2-propynylphenethylamine
|
|
gptkbp:KEGGID
|
D00267
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
selective MAO-B inhibitor
|
|
gptkbp:MeSH_ID
|
D003704
|
|
gptkbp:metabolism
|
amphetamine
|
|
gptkbp:molecularWeight
|
191.28 g/mol
|
|
gptkbp:otherName
|
gptkb:selegiline
|
|
gptkbp:PubChem_CID
|
gptkb:DB01037
26757
CHEMBL1131
24932
|
|
gptkbp:relatedTo
|
gptkb:rasagiline
pargyline
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
|
|
gptkbp:sideEffect
|
nausea
dizziness
insomnia
hallucinations
|
|
gptkbp:UNII
|
6U8X9A1E42
|
|
gptkbp:usedFor
|
treatment of major depressive disorder
treatment of Parkinson's disease
|
|
gptkbp:bfsParent
|
gptkb:Selegiline
gptkb:selegiline
|
|
gptkbp:bfsLayer
|
7
|